Trend
DailyUptrend (starting)
4 hourExpanding
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $12.13
Key levels
Resistance$9.22
Resistance$7.56
Latest news & SEC filings
AnalystAnalysts downgrade NeuroPace after Q3 revenue miss
AnalystKeybanc keeps Overweight rating on NeuroPace, cuts price target to $14
AnalystLeerink Partners cuts NeuroPace rating to Market Perform with $7 target
All NPCE news →NeuroPace is a medical device company that makes the RNS System, an implantable neuromodulation device for grown patients whose focal seizures do not respond to medication. The device tracks electrical signals in the brain, spots each person's unique seizure-related activity, and responds with small electrical pulses to head off seizures. It also logs brain activity that doctors can review in person or from a distance. The company sells mainly in the United States, with limited distribution in Israel and Canada.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
SEPT Low Target
$18.00
SEPT Mid Target
$19.00
SEPT High Target
$22.00
Analyst Consensus
$19.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NPCE.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$14.47
33
Moat Score
NONE
5/9
Piotroski Score
-3.1
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Morrell Martha | officer | Sale | 335 | $5K | Sep 24, 2026 |
| Williams Patrick F. | officer | Sale | 1,162 | $17K | Sep 20, 2026 |
| Becker Joel | director officer | Sale | 1,310 | $19K | Sep 3, 2026 |
| Morrell Martha | officer | Sale | 358 | $5K | Aug 27, 2026 |
| Becker Joel | director officer | Sale | 1,126 | $16K | Aug 27, 2026 |
| Kumar Rakhi | director | Buy | 2,890 | - | Jun 5, 2026 |
| Ryan Renee | director | Buy | 2,890 | - | Jun 5, 2026 |
| Huennekens R Scott | director | Buy | 2,890 | - | Jun 5, 2026 |
| Andrade Lisa | director | Buy | 2,890 | - | Jun 5, 2026 |
| Geiger Uri | director | Buy | 2,890 | - | Jun 5, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
25.1%
3yr Revenue CAGR
30.0%
EPS Growth YoY
29.03%
FCF Growth YoY
37.9%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for NPCE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:26:36 | $5.68 | 1,000 | $$6K | SELL |
| 15:26:06 | $5.67 | 1,000 | $$6K | SELL |
| 15:26:00 | $5.66 | 1,000 | $$6K | BUY |
| 15:25:28 | $5.63 | 2,000 | $$11K | MIDPOINT |
| 15:24:02 | $5.50 | 1,000 | $$6K | BUY |
5 dark pool trades shown · $$34K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for NeuroPace Inc (NPCE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NeuroPace Inc (NPCE) is at $5.63, down 53.16% (-$6.39) at the Nov 13, 2026 close.
Latest NPCE news — Nov 13, 2026: Analysts downgrade NeuroPace after Q3 revenue miss · Nov 13, 2026: Keybanc keeps Overweight rating on NeuroPace, cuts price target to $14
The average analyst price target for NPCE is $19.00, ranging from $18 to $22, based on 4 analysts. Latest: Neuropace upgrade on Sep 18, 2026.
Analyst ratings for NPCE: 2 Buy, 2 Hold, 0 Sell — consensus Hold.
NPCE last reported on Aug 11, 2026: EPS -$0.18 vs -$0.22 expected — a beat of 17.4%.
NPCE does not currently pay a dividend.
Resistance: $7.56, $9.22, $9.92.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 13, 2026: Analysts downgrade NeuroPace after Q3 revenue miss · Nov 13, 2026: Keybanc keeps Overweight rating on NeuroPace, cuts price target to $14 · Nov 13, 2026: Leerink Partners cuts NeuroPace rating to Market Perform with $7 target